MX2017000578A - Tratamiento de cancer con una combinacion de radiacion, nanoparticulas de oxido de cerio y un agente quimioterapeutico. - Google Patents

Tratamiento de cancer con una combinacion de radiacion, nanoparticulas de oxido de cerio y un agente quimioterapeutico.

Info

Publication number
MX2017000578A
MX2017000578A MX2017000578A MX2017000578A MX2017000578A MX 2017000578 A MX2017000578 A MX 2017000578A MX 2017000578 A MX2017000578 A MX 2017000578A MX 2017000578 A MX2017000578 A MX 2017000578A MX 2017000578 A MX2017000578 A MX 2017000578A
Authority
MX
Mexico
Prior art keywords
cerium oxide
radiation
oxide nanoparticles
cancer
treatment
Prior art date
Application number
MX2017000578A
Other languages
English (en)
Inventor
Baker Cheryl
Original Assignee
Biocurity Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocurity Holdings Inc filed Critical Biocurity Holdings Inc
Publication of MX2017000578A publication Critical patent/MX2017000578A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se dirige a métodos para el tratamiento de cáncer con una combinación de radiación, nanopartículas de óxido de cerio y al menos un agente quimioterapéutico. Las nanopartículas de óxido de cerio (CONPs) son cristales del tamaño de nanómetro de óxido de cerio, que varían típicamente entre aproximadamente un nanómetro a aproximadamente 20 nanómetros en la dimensión más larga. Los presentes métodos usan nanopartículas de óxido de cerio para mejorar la muerte de células cancerosas inducidas por radiación e inducidas por quimioterapia y también para reducir la toxicidad asociada con la terapia de radiación y quimioterapia.
MX2017000578A 2014-07-17 2015-07-17 Tratamiento de cancer con una combinacion de radiacion, nanoparticulas de oxido de cerio y un agente quimioterapeutico. MX2017000578A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462025861P 2014-07-17 2014-07-17
PCT/US2015/040869 WO2016011328A1 (en) 2014-07-17 2015-07-17 Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent

Publications (1)

Publication Number Publication Date
MX2017000578A true MX2017000578A (es) 2017-07-20

Family

ID=55079076

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017000578A MX2017000578A (es) 2014-07-17 2015-07-17 Tratamiento de cancer con una combinacion de radiacion, nanoparticulas de oxido de cerio y un agente quimioterapeutico.

Country Status (9)

Country Link
EP (2) EP3628308A1 (es)
JP (2) JP6706255B2 (es)
CN (2) CN111184733A (es)
AU (1) AU2015289504B2 (es)
BR (1) BR112017000800A8 (es)
CA (1) CA2955384C (es)
MX (1) MX2017000578A (es)
RU (2) RU2704811C2 (es)
WO (1) WO2016011328A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10512761B2 (en) 2009-12-02 2019-12-24 Renovorx, Inc. Methods for delivery of therapeutic materials to treat pancreatic cancer
WO2014197362A1 (en) 2013-06-03 2014-12-11 Ramtin Agah Devices, methods and kits for delivery of therapeutic materials to a pancreas
CN111184733A (zh) * 2014-07-17 2020-05-22 生物安全药品有限公司 用放射、氧化铈纳米颗粒、和化疗剂的组合治疗癌症
WO2017174437A1 (en) * 2016-04-05 2017-10-12 Hospital Clínic De Barcelona Ceria nanoparticles for use in the treatment of hepatocellular carcinoma
WO2018134254A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CA3063115A1 (en) * 2017-04-12 2018-10-18 Vikash J. BHAGWANDIN Compositions, packaged pharmaceuticals, and methods of using posaconazole for the sensitization of resistant tumors
US10695543B2 (en) 2017-05-18 2020-06-30 Renovorx, Inc. Methods for treating cancerous tumors
US11052224B2 (en) 2017-05-18 2021-07-06 Renovorx, Inc. Methods for treating cancerous tumors
WO2019124603A1 (ko) * 2017-12-22 2019-06-27 경상대학교병원 Iwr-1을 유효성분으로 함유하는 켈로이드 예방 또는 치료용 조성물
KR102102535B1 (ko) * 2018-07-26 2020-04-21 서울대학교산학협력단 방사선 보호 나노입자
WO2020069292A1 (en) * 2018-09-28 2020-04-02 The Regents Of The University Of Colorado, A Body Corporate Methods for preventing and treating pulmonary inflammation and fibrosis
RU2699670C1 (ru) * 2018-11-16 2019-09-09 Объединенный Институт Ядерных Исследований (Оияи) Способ повышения частоты образования двунитевых разрывов днк в клетках человека при действии ионизирующих излучений в условиях влияния радиомодификаторов
CA3181177A1 (en) * 2020-04-30 2021-10-04 University Of Central Florida Research Foundation, Inc. Dispensable nanoparticle based composition for disinfection
WO2023025291A1 (zh) 2021-08-27 2023-03-02 深圳艾欣达伟医药科技有限公司 冻干制剂溶液及冻干制剂、方法和用途
WO2023025312A1 (zh) 2021-08-27 2023-03-02 深圳艾欣达伟医药科技有限公司 使用th-302治疗parp抑制剂耐药的患者

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6099798A (en) 1997-10-31 2000-08-08 Nanogram Corp. Ultraviolet light block and photocatalytic materials
TWI323662B (en) * 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
WO2007002662A2 (en) * 2005-06-27 2007-01-04 Edward Via Virginia College Of Osteopathic Medicine Anti-inflammatory, radioprotective, and longevity enhancing capabilities of cerium oxide nanoparticles
US20090181997A1 (en) * 2007-12-27 2009-07-16 Grayzel David Therapeutic cancer treatments
WO2009132277A1 (en) * 2008-04-25 2009-10-29 The Board Of Regents Of The University Of Oklahoma Inhibition of neovascularization by cerium oxide nanoparticles
US20100015042A1 (en) * 2008-07-03 2010-01-21 Ramot At Tel Aviv University Ltd. Combine radiation therapy and chemotherapy for treating cancer
GB0921596D0 (en) * 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
CA2791990A1 (en) * 2010-03-01 2011-09-09 Intraop Medical Corporation Radiotherapy combined with hypoxic cell sensitizers
US20120251496A1 (en) * 2011-03-31 2012-10-04 Telik, Inc. Ezatiostat for treating multiple myeloma
CA2869554A1 (en) * 2012-04-04 2013-10-10 Duke University Methods of using cerium oxide nanoparticles to mitigate or protect against radiation injury
DK2861212T3 (en) * 2012-06-13 2017-03-06 Cerion Llc Cerium oxide nanoparticles for the treatment of oxidative stress
WO2014088920A1 (en) * 2012-12-06 2014-06-12 Merck Sharp & Dohme Corp. Disulfide masked prodrug compositions and methods
ES2733551T3 (es) * 2014-04-25 2019-11-29 Univ Michigan Regents Nanopartículas para uso en la terapia del cáncer
CN111184733A (zh) * 2014-07-17 2020-05-22 生物安全药品有限公司 用放射、氧化铈纳米颗粒、和化疗剂的组合治疗癌症
GB201506381D0 (en) * 2015-04-15 2015-05-27 Isis Innovation Embolization particle

Also Published As

Publication number Publication date
CA2955384A1 (en) 2016-01-21
RU2704811C2 (ru) 2019-10-31
RU2017104909A3 (es) 2019-01-28
CA2955384C (en) 2024-03-12
JP2020158507A (ja) 2020-10-01
AU2015289504A1 (en) 2017-02-23
AU2015289504B2 (en) 2020-12-17
EP3628308A1 (en) 2020-04-01
EP3169312A4 (en) 2017-12-27
EP3169312B1 (en) 2020-09-02
CN111184733A (zh) 2020-05-22
EP3169312A1 (en) 2017-05-24
BR112017000800A8 (pt) 2023-04-25
JP6706255B2 (ja) 2020-06-03
JP2017521499A (ja) 2017-08-03
CN106604719B (zh) 2019-11-26
BR112017000800A2 (pt) 2018-07-03
RU2017104909A (ru) 2018-08-17
CN106604719A (zh) 2017-04-26
WO2016011328A1 (en) 2016-01-21
RU2019133284A (ru) 2019-12-05

Similar Documents

Publication Publication Date Title
MX2017000578A (es) Tratamiento de cancer con una combinacion de radiacion, nanoparticulas de oxido de cerio y un agente quimioterapeutico.
CL2018003316A1 (es) Compuestos para la inhibición de k-ras y para el tratamiento del cáncer. (divisional solicitud 201702786)
MX2016015363A (es) Terapias de combinacion para el tratamiento de cancer.
GB201719076D0 (en) Particles for the treatment of cancer in combination with radiotherapy
CL2017003457A1 (es) Metodos para tratar tumores solidos usando terapia de combinacion del inhibidor de nanoparticulas mtor.
MX2022008902A (es) Articulo abrasivo que incluye particulas abrasivas conformadas.
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
MX2017007321A (es) Terapias de combinacion.
MX2015011753A (es) Metodos para tratar cancer de vegija.
PH12017550063A1 (en) Combination therapies for treating cancers
MX2021007794A (es) Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones.
PH12015501486A1 (en) Nanoparticle compositions of albumin and paclitaxel
CL2018000222A1 (es) Nueva combinación para el uso en el tratamiento del cáncer
TW201613887A (en) Antiproliferative compounds and methods of use thereof
MX343671B (es) Metodos de tratamiento de cancer de vejiga.
SG10201907684PA (en) Androgen receptor modulator and uses thereof
MX2015011783A (es) Metodos para tratar tumores solidos pediatricos.
MX2016004678A (es) Composiciones para el tratamiento del cancer.
BR112015029386A2 (pt) uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer
MX2016004441A (es) Tratamiento del cancer con una combinacion de plinabulina y taxano.
MX370662B (es) Composiciones que comprenden nanopartículas de paclitaxel y albúmina para usarse en el tratamiento de cáncer.
WO2019126739A8 (en) Pyrvinium pamoate anti-cancer therapies
MX2016000131A (es) Nanoparticulas polimericas de docetaxel para el tratamiento de cancer.
UY35082A (es) Sustancia portadora de oxigeno basada en la hemoglobina que contiene una composicion farmaceutica para el tratamiento del cancer y la la prevencion de la recurrencia del cancer
MX2019010852A (es) Nanoparticulas a base de lipidos con estabilidad mejorada.